Waldenström's macroglobulinaemia

Blood Reviews

Volumn 16, Issue 3, 2002, Pages 175-184

  Johnson, S A ^a   Oscier, D G ^b   Leblond, V ^c  

^a TAUNTON AND SOMERSET HOSPITAL   (United Kingdom)

^b ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Chlorambucil; Cladribine; Diagnosis; Fludarabine; Rituximab; Transplantation; Treatment; Waldenstr m's macroglobulinaemia

Indexed keywords

ALEMTUZUMAB; ALKYLATING AGENT; ALPHA INTERFERON; CD19 ANTIGEN; CD20 ANTIGEN; CD23 ANTIGEN; CD5 ANTIGEN; CHLORAMBUCIL; CLADRIBINE; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; GAMMA INTERFERON; IMMUNOGLOBULIN D; IMMUNOGLOBULIN M; MELPHALAN; MONOCLONAL ANTIBODY; PREDNISOLONE; PURINE DERIVATIVE; RITUXIMAB; ANTINEOPLASTIC AGENT;

ALLOTRANSPLANTATION; AUTOTRANSPLANTATION; BONE MARROW CELL; CHRONIC DISEASE; CLINICAL TRIAL; DRUG CHOICE; GERMINAL CENTER; HISTOPATHOLOGY; HUMAN; IMMUNOGLOBULIN VARIABLE REGION; LYMPHOCYTIC INFILTRATION; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; META ANALYSIS; PHENOTYPE; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; SURVIVAL; TREATMENT OUTCOME; VISCOSITY; WALDENSTROEM MACROGLOBULINEMIA; DIFFERENTIAL DIAGNOSIS; RESEARCH;

ANTINEOPLASTIC AGENTS; DIAGNOSIS, DIFFERENTIAL; HUMANS; RESEARCH; TREATMENT OUTCOME; WALDENSTROM MACROGLOBULINEMIA;

EID: 0036729171     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-960X(02)00016-4     Document Type: Article

References (52)

1. Lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia
2. Waldenström macroglobulinaemia caused by extranodal marginal zone B-cell lymphoma
3. Typical Waldenström's macroglobulinaemia and IgM-secreting MGUS are each derived from B-cells arrested following cessation of somatic mutation but prior to isotype switch events
4. Heavy chain somatic hypermutation status in Waldenström's macroglobulinaemia
5. Cytogenetic findings in lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia
6. Genomic aberrations in Waldenström's macroglobulinaemia clonal cells detected by FISH
7. t(9;14) (p13;q32) denotes a subset of low-grade non-Hodgkins lymphoma with plasmacytoid differentiation
8. The t(9;14) (p13;q32) chromosomal translocation associated with lymphoplasmacytoid lymphoma involves the PAX-5 gene
9. Clinicopathological correlates of IgM paraproteinemias
10. The spectrum of IgM monoclonal gammopathy in 430 cases
11. Study of prognosis in Waldenström's macroglobulinemia: A proposal for a simple binary classification with clinical and investigational utility
12. Prognostic factors in Waldenström's macroglobulinemia: A report of 167 cases
13. Prognostic factors in Waldenström macroglobulinemia: A report on 232 patients with the description of a new scoring system and its validation on 253 other patients
14. Waldenströms macroglobulinaemia. Development of diagnostic criteria and identification of prognostic factors
15. Waldenström macroglobulinaemia: Presenting features and outcome in a series with 217 cases
16. Prognostic factors and response to fludarabine therapy in patients with Waldenström macroglobulinemia: Results of United States intergroup trial (South West Oncology Group S9003)
17. Plasmapheresis for hyperviscosity syndrome in macroglobulinemia Waldenström and multiple myeloma: Influence on blood rheology and the microcirculation
18. Plasma exchange in the long-term management of Waldenström's macroglobulinemia
19. Therapeutic plasma exchange: An update from the Canadian Apheresis Group
20. Waldenström's macroglobulinaemia
21. Waldenström's macroglobulinemia: A prospective study comparing daily with intermittent oral chlorambucil
22. Waldenström's macroglobulinemia: Long term results with the M-2 protocol
23. Waldenström's macroglobulinemia: Results of a combined oral treatment in 34 newly diagnosed patients
24. Fludarabine therapy in Waldenström's macroglobulinemia
25. Fludarabine therapy in macroglobulinemic lymphoma
26. Fludarabine treatment in resistant Waldenström's macroglobulinemia
27. Activity of fludarabine in previously treated Waldenström's macroglobulinemia: A report of 71 cases
28. Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenström macroglobulinemia in first relapse or with primary refractory disease
29. Multicentre phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenström's macroglobulinaemia and Mantle Cell Lymphoma
30. Treatment of Waldenström macroglobulinemia with 2-chlorodeoxyadenosine
31. Primary therapy of Waldenström's macroglobulinemia with 2-chlorodeoxyadenosine
32. Treatment of Waldenström's macroglobulinemia resistant to standard therapy with 2-chlorodeoxyadenosine: Identification of prognostic factors
33. Cladribine for Waldenström's macroglobulinemia
34. Cladribine (2-CDA) given as subcutaneous bolus injections is active in pre-treated Waldenström's macroglobulinaemia
35. Bolus administration of cladribine in the treatment of Waldenström macroglobulinaemia
36. 2-Chlorodeoxyadenosine treatment of Waldenström's macroglobulinemia - The analysis of own experience and the review of literature
37. French Co-operative Group on CLL and macroglobulinemia. Evaluating treatment strategies in advanced Waldenström macroglobulinemia: Use of quality-adjusted survival analysis
38. A phase II trial on alpha-interferon (aIFN) effect in patients with monoclonal IgM gammopathy
39. Recombinant interferon gamma in hairy cell leukemia, multiple myeloma, and Waldenström's macroglobulinemia
40. Rituximab therapy in Waldenström's macroglobulinemia: Preliminary evidence of clinical activity
41. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma
42. CD20-Directed antibody-mediated Immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenström's macroglobulinemia
43. Treatment of Waldenström's macroglobulinaemia with thalidomide
44. Treatment of resistant Waldenström's macroglobulinemia with high dose glucocorticosteroids
45. Successful doxorubicin therapy of primary macroglobulinemia resistant to alkylating agents
46. Primary therapy of Waldenström's macroglobulinemia with paclitaxel
47. Autologous peripheral stem cell transplantation for Waldenström's macroglobulinaemia
48. High dose therapy with autologous haemopoietic stem cell support for Waldenström's macroglobulinemia
49. Myeloablative radiochemotherapy followed by reinfusion of purged autologous stem cells for Waldenström's macroglobulinaemia
50. High-dose chemotherapy followed by stem cell transplantation in patient with resistant Waldenström's macroglobulinemia
51. Allogeneic bone marrow transplantation for advanced Waldenstrom's macroglobulinemia
52. Successful non-myeloablative allogeneic peripheral blood stem cell transplantation (PBSCT) for Waldenström's macroglobulinaemia with severe pancytopenia